First-in-human study with CRISPR/Cas9-based gene editing in transthyretin amyloidosis with cardiomyopathy
This video was recorded during the AHA Scientific Sessions 2022 in Chicago, IL, USA.
Prof. Julian D. Gillmore, MD, PhD - London, UK
This recording was developed under auspices of EPCCS. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of EPCCS.